Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LUCAR-G79D

Cell therapy · developed by Nanjing Legend Biotech

Phase 1 Most advanced trial
LEGN Developer
1 Registered trials

What is LUCAR-G79D?

LUCAR-G79D is a T-cell therapy given by infusion after a conditioning regimen of cyclophosphamide and fludarabine. It is studied in systemic lupus erythematosus and idiopathic inflammatory myopathies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Immunology
Developer
Nanjing Legend Biotech Co. (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07331272 Phase 1 Systemic Lupus Erythematosus (SLE) Recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Inflammatory Myopathies(IIM)Systemic Lupus Erythematosus (SLE)

More from Nanjing Legend Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LUCAR-G79D

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.